Seattle Genetics and Merck & Co Announce Two Strategic Oncology Collaborations

Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock

16-Sep-2020 - Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting ...

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

Companies to combine proprietary technologies to generate novel ADC product candidates

15-Sep-2011 - Seattle Genetics, Inc. and Oxford BioTherapeutics (OBT) announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens ...

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

16-Sep-2010 - Genmab A/S and Seattle Genetics, Inc. announced that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize Seattle Genetics’ ADC technology with its HuMax-TF antibody targeting the Tissue Factor ...

Seattle Genetics Announces Antibody-Drug Conjugate Agreement with Bayer Pharmaceuticals

29-Sep-2004 - Bothell. Seattle Genetics, Inc. announced that Bayer Pharmaceuticals Corporation has licensed Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. The license provides Bayer with rights to utilize Seattle Genetics' ADC technology to link cell-killing drugs to antibodies against ...